



Clinical trial results:

A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico

Summary

EudraCT number	2009-017122-39
Trial protocol	Outside EU/EEA
Global end of trial date	30 March 2010

Results information

Result version number	v1 (current)
This version publication date	29 June 2016
First version publication date	01 August 2015

Trial information

Trial identification

Sponsor protocol code	6096A1-3009
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00708682
WHO universal trial number (UTN)	-
Other trial identifiers	alias: B1851045

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 August 2010
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	30 March 2010
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the pneumococcal immune responses induced by 13 valent pneumococcal conjugate vaccine (13vPnC) when measured 1 month after the 3-dose infant series.
To evaluate the acceptability of the safety profile of 13vPnC as measured by the incidence rates of local reactions, systemic events, and adverse events (AEs).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	10 July 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Mexico: 225
Worldwide total number of subjects	225
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	2
Infants and toddlers (28 days-23 months)	223
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Study was conducted in Mexico from 10 July 2008 to 30 March 2010.

Period 1

Period 1 title	Infant Series
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	13vPnC Infant Series
------------------	----------------------

Arm description:

13vPnC administered at 2, 4, and 6 months of age (infant series).

Arm type	Experimental
Investigational medicinal product name	13vPnC
Investigational medicinal product code	
Other name	Prevenar 13
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

13vPnC 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series).

Number of subjects in period 1	13vPnC Infant Series
Started	225
Vaccinated Dose 1	223
Vaccinated Dose 2	214
Vaccinated Dose 3	194
Completed	192
Not completed	33
Adverse Event	1
'Not Specified '	19
Protocol Violation	1
Failed to Return	2
Lost to follow-up	4
Parent/Legal Guardian Request	6

Period 2

Period 2 title	After Infant Series
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	13vPnC After Infant Series
Arm description: Included subjects who received 13vPnC at 2, 4, and 6 months of age (infant series).	
Arm type	No intervention
No investigational medicinal product assigned in this arm	

Number of subjects in period 2	13vPnC After Infant Series
Started	192
Completed	191
Not completed	1
Parent/Legal Guardian Request	1

Period 3

Period 3 title	Toddler Dose
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	13vPnC Toddler Dose
Arm description: 13vPnC administered at 12 months of age (toddler dose).	
Arm type	Experimental
Investigational medicinal product name	13vPnC
Investigational medicinal product code	
Other name	Prevenar 13
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

13vPnC 0.5 mL dose administered IM at 12 months of age (toddler dose).

Number of subjects in period 3	13vPnC Toddler Dose
Started	191
Completed	183
Not completed	8
Failed to Return	4
Parent/Legal Guardian Request	1
Lost to follow-up	3

Baseline characteristics

Reporting groups

Reporting group title	13vPnC Infant Series
-----------------------	----------------------

Reporting group description:

13vPnC administered at 2, 4, and 6 months of age (infant series).

Reporting group values	13vPnC Infant Series	Total	
Number of subjects	225	225	
Age categorical Units: Subjects			
Age continuous Units: months arithmetic mean standard deviation	2.1 ± 0.5	-	
Gender categorical Units: Subjects			
Female	109	109	
Male	116	116	

End points

End points reporting groups

Reporting group title	13vPnC Infant Series
Reporting group description: 13vPnC administered at 2, 4, and 6 months of age (infant series).	
Reporting group title	13vPnC After Infant Series
Reporting group description: Included subjects who received 13vPnC at 2, 4, and 6 months of age (infant series).	
Reporting group title	13vPnC Toddler Dose
Reporting group description: 13vPnC administered at 12 months of age (toddler dose).	

Primary: Percentage of Subjects Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (\geq) 0.35 Micrograms Per Milliliter (Mcg/mL), 1 Month After the Infant Series

End point title	Percentage of Subjects Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (\geq) 0.35 Micrograms Per Milliliter (Mcg/mL), 1 Month After the Infant Series ^[1]
End point description: Percentage of subjects achieving predefined antibody threshold ≥ 0.35 mcg/mL, along with the corresponding 95 percent confidence interval (95% CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of subjects. Evaluable 3-Dose Infant Immunogenicity population: eligible subjects who received treatments as assigned at all 3 doses, blood drawn within specified time frames, at least 1 valid and determinate assay result for proposed analysis, and no major protocol violations.	
End point type	Primary
End point timeframe: 1 month after the infant series (7 months of age)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported for this end point.

End point values	13vPnC Infant Series			
Subject group type	Reporting group			
Number of subjects analysed	171			
Units: Percentage of Subjects				
number (confidence interval 95%)				
Common serotypes - serotype 4	100 (97.9 to 100)			
Common serotypes - serotype 6B	97.7 (94.1 to 99.4)			
Common serotypes - serotype 9V	98.2 (94.9 to 99.6)			
Common serotypes - serotype 14	98.8 (95.8 to 99.9)			
Common serotypes - serotype 18C	98.8 (95.8 to 99.9)			
Common serotypes - serotype 19F	98.2 (95 to 99.6)			

Common serotypes - serotype 23F	92.9 (87.9 to 96.3)			
Additional serotypes - serotype 1	99.4 (96.8 to 100)			
Additional serotypes - serotype 3	94.1 (89.4 to 97.1)			
Additional serotypes - serotype 5	98.2 (95 to 99.6)			
Additional serotypes - serotype 6A	98.8 (95.8 to 99.9)			
Additional serotypes - serotype 7F	98.8 (95.8 to 99.9)			
Additional serotypes - serotype 19A	99.4 (96.8 to 100)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving Serotype-specific Pneumococcal IgG Antibody Level $\geq 0.35\text{mcg/mL}$, 1 Month After Dose 2 of the Infant Series

End point title	Percentage of Subjects Achieving Serotype-specific Pneumococcal IgG Antibody Level $\geq 0.35\text{mcg/mL}$, 1 Month After Dose 2 of the Infant Series
-----------------	---

End point description:

Percentage of subjects achieving predefined antibody threshold $\geq 0.35\text{mcg/mL}$, along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of subjects. Evaluable 2-Dose Infant Immunogenicity population: eligible subjects who received treatments as assigned at dose 1 and dose 2, blood drawn within specified time frames, at least 1 valid and determinate assay result for proposed analysis, and no major protocol violations.

End point type	Secondary
----------------	-----------

End point timeframe:

1 month after dose 2 of the infant series (5 months of age)

End point values	13vPnC Infant Series			
Subject group type	Reporting group			
Number of subjects analysed	195			
Units: Percentage of Subjects				
number (confidence interval 95%)				
Common serotypes - serotype 4	100 (98.1 to 100)			
Common serotypes - serotype 6B	80.9 (74.7 to 86.2)			
Common serotypes - serotype 9V	95.9 (92.1 to 98.2)			
Common serotypes - serotype 14	99 (96.3 to 99.9)			
Common serotypes - serotype 18C	93.3 (88.9 to 96.4)			

Common serotypes - serotype 19F	98.5 (95.5 to 99.7)			
Common serotypes - serotype 23F	77.9 (71.5 to 83.6)			
Additional serotypes - serotype 1	98.5 (95.6 to 99.7)			
Additional serotypes - serotype 3	96.4 (92.7 to 98.5)			
Additional serotypes - serotype 5	97.4 (94.1 to 99.2)			
Additional serotypes - serotype 6A	94.9 (90.8 to 97.5)			
Additional serotypes - serotype 7F	99 (96.3 to 99.9)			
Additional serotypes - serotype 19A	99.5 (97.2 to 100)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving Serotype-specific Pneumococcal IgG Antibody Concentration ≥ 0.35 mcg/mL, 1 Month After the Toddler Dose

End point title	Percentage of Subjects Achieving Serotype-specific Pneumococcal IgG Antibody Concentration ≥ 0.35 mcg/mL, 1 Month After the Toddler Dose
-----------------	---

End point description:

Percentage of subjects achieving predefined antibody threshold ≥ 0.35 mcg/mL, along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of subjects. Evaluable Toddler Immunogenicity population: eligible subjects who received treatments as assigned at all 3 doses of the infant series and at the toddler dose, blood drawn within specified time frames, at least 1 valid and determinate assay result for proposed analysis, and no major protocol violations.

End point type	Secondary
----------------	-----------

End point timeframe:

1 month after the toddler dose (13 months of age)

End point values	13vPnC Toddler Dose			
Subject group type	Reporting group			
Number of subjects analysed	155			
Units: Percentage of Subjects				
number (confidence interval 95%)				
Common serotypes - serotype 4	100 (97.6 to 100)			
Common serotypes - serotype 6B	99.4 (96.5 to 100)			
Common serotypes - serotype 9V	100 (97.6 to 100)			
Common serotypes - serotype 14	100 (97.6 to 100)			

Common serotypes - serotype 18C	100 (97.6 to 100)			
Common serotypes - serotype 19F	100 (97.6 to 100)			
Common serotypes - serotype 23F	99.4 (96.5 to 100)			
Additional serotypes - serotype 1	100 (97.6 to 100)			
Additional serotypes - serotype 3	96.7 (92.5 to 98.9)			
Additional serotypes - serotype 5	100 (97.6 to 100)			
Additional serotypes - serotype 6A	100 (97.6 to 100)			
Additional serotypes - serotype 7F	100 (97.6 to 100)			
Additional serotypes - serotype 19A	100 (97.6 to 100)			

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal IgG Antibody After Dose 2 of the Infant Series

End point title	Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal IgG Antibody After Dose 2 of the Infant Series
-----------------	--

End point description:

Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all subjects with available data for the specified blood draw. Evaluable 2-Dose Infant Immunogenicity population.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

1 month after dose 2 of infant series (5 months of age)

End point values	13vPnC Infant Series			
Subject group type	Reporting group			
Number of subjects analysed	195			
Units: mcg/mL				
geometric mean (confidence interval 95%)				
Common serotypes - serotype 4	3.54 (3.16 to 3.97)			
Common serotypes - serotype 6B	0.84 (0.71 to 0.98)			
Common serotypes - serotype 9V	1.82 (1.6 to 2.08)			
Common serotypes - serotype 14	5.54 (4.72 to 6.5)			

Common serotypes - serotype 18C	1.8 (1.56 to 2.07)			
Common serotypes - serotype 19F	4.14 (3.59 to 4.78)			
Common serotypes - serotype 23F	0.84 (0.71 to 0.99)			
Additional serotypes - serotype 1	3.41 (3 to 3.89)			
Additional serotypes - serotype 3	1.11 (1.01 to 1.23)			
Additional serotypes - serotype 5	1.89 (1.67 to 2.13)			
Additional serotypes - serotype 6A	1.86 (1.6 to 2.16)			
Additional serotypes - serotype 7F	2.98 (2.7 to 3.29)			
Additional serotypes - serotype 19A	3.52 (3.07 to 4.03)			

Statistical analyses

No statistical analyses for this end point

Other pre-specified: GMC for Serotype-specific Pneumococcal IgG Antibody After Dose 3 of the Infant Series

End point title	GMC for Serotype-specific Pneumococcal IgG Antibody After Dose 3 of the Infant Series
-----------------	---

End point description:

Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 7vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all subjects with available data for the specified blood draw. Evaluable 3-Dose Infant Immunogenicity population.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

1 month after dose 3 of infant series (7 months of age)

End point values	13vPnC Infant Series			
Subject group type	Reporting group			
Number of subjects analysed	171			
Units: mcg/mL				
geometric mean (confidence interval 95%)				
Common serotypes - serotype 4	3.48 (3.12 to 3.88)			
Common serotypes - serotype 6B	5.02 (4.27 to 5.9)			
Common serotypes - serotype 9V	2.34 (2.11 to 2.6)			
Common serotypes - serotype 14	9.35 (8.07 to 10.82)			

Common serotypes - serotype 18C	2.5 (2.23 to 2.81)			
Common serotypes - serotype 19F	3.75 (3.28 to 4.29)			
Common serotypes - serotype 23F	1.83 (1.55 to 2.17)			
Additional serotypes - serotype 1	4.23 (3.73 to 4.79)			
Additional serotypes - serotype 3	1.17 (1.03 to 1.33)			
Additional serotypes - serotype 5	3.11 (2.75 to 3.52)			
Additional serotypes - serotype 6A	4.08 (3.56 to 4.68)			
Additional serotypes - serotype 7F	3.71 (3.34 to 4.12)			
Additional serotypes - serotype 19A	4.19 (3.71 to 4.74)			

Statistical analyses

No statistical analyses for this end point

Other pre-specified: GMC for Serotype-specific Pneumococcal IgG Antibody After the Toddler Dose

End point title	GMC for Serotype-specific Pneumococcal IgG Antibody After the Toddler Dose
-----------------	--

End point description:

Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 7vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all subjects with available data after the toddler dose. Evaluable Toddler Immunogenicity population subset.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

1 month after toddler dose (13 months of age)

End point values	13vPnC Toddler Dose			
Subject group type	Reporting group			
Number of subjects analysed	137 ^[2]			
Units: mcg/mL				
geometric mean (confidence interval 95%)				
Common serotypes - serotype 4	5.1 (4.41 to 5.89)			
Common serotypes - serotype 6B	15.41 (12.92 to 18.38)			
Common serotypes - serotype 9V	3.76 (3.29 to 4.29)			
Common serotypes - serotype 14	10.62 (9.16 to 12.32)			

Common serotypes - serotype 18C	3.93 (3.45 to 4.48)			
Common serotypes - serotype 19F	11.33 (9.68 to 13.26)			
Common serotypes - serotype 23F	5.7 (4.81 to 6.77)			
Additional serotypes - serotype 1	5.86 (5.08 to 6.75)			
Additional serotypes - serotype 3	1.62 (1.42 to 1.84)			
Additional serotypes - serotype 5	4.75 (4.18 to 5.4)			
Additional serotypes - serotype 6A	11.64 (9.93 to 13.64)			
Additional serotypes - serotype 7F	5.81 (5.18 to 6.51)			
Additional serotypes - serotype 19A	8.95 (7.84 to 10.23)			

Notes:

[2] - Subjects who had valid, determinate assay result for antibody GMC at infant dose 3 and toddler dose.

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Percentage of Subjects Reporting Pre-specified Local Reactions: Infant Series Dose 1 (2 Months of Age)

End point title	Percentage of Subjects Reporting Pre-specified Local Reactions: Infant Series Dose 1 (2 Months of Age)
-----------------	--

End point description:

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (greater than [$>$] 7.0 cm). Subjects may be represented in more than 1 category. Safety population: All subjects who received at least 1 dose of the study vaccine.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Within 4 days after dose 1 of Infant Series (2 months of age)

End point values	13vPnC Infant Series			
Subject group type	Reporting group			
Number of subjects analysed	214 ^[3]			
Units: Percentage of Subjects				
number (not applicable)				
Tenderness: Any	63.5			
Tenderness: Significant	12.4			
Swelling: Any	31.2			
Swelling: Mild	25.1			
Swelling: Moderate	11.9			
Swelling: Severe	0			
Redness: Any	33.8			
Redness: Mild	27.9			

Redness: Moderate	10.6			
Redness: Severe	0			

Notes:

[3] - Subjects reporting yes for at least 1 day or no for all days for any local reaction.

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Percentage of Subjects Reporting Pre-specified Local Reactions: Infant Series Dose 2 (4 Months of Age)

End point title	Percentage of Subjects Reporting Pre-specified Local Reactions: Infant Series Dose 2 (4 Months of Age)
-----------------	--

End point description:

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (>7.0 cm). Subjects may be represented in more than 1 category. Safety population.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Within 4 days after dose 2 of Infant Series (4 months of age)

End point values	13vPnC Infant Series			
Subject group type	Reporting group			
Number of subjects analysed	196 ^[4]			
Units: Percentage of Subjects				
number (not applicable)				
Tenderness: Any	69.4			
Tenderness: Significant	12.6			
Swelling: Any	29.9			
Swelling: Mild	20			
Swelling: Moderate	13.3			
Swelling: Severe	0			
Redness: Any	28.9			
Redness: Mild	19.5			
Redness: Moderate	12.3			
Redness: Severe	0			

Notes:

[4] - Subjects reporting yes for at least 1 day or no for all days for any local reaction.

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Percentage of Subjects Reporting Pre-specified Local Reactions: Infant Series Dose 3 (6 Months of Age)

End point title	Percentage of Subjects Reporting Pre-specified Local Reactions: Infant Series Dose 3 (6 Months of Age)
-----------------	--

End point description:

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (>7.0 cm). Subjects may be represented in more than 1 category. Safety population.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Within 4 days after dose 3 (6 months of age)

End point values	13vPnC Infant Series			
Subject group type	Reporting group			
Number of subjects analysed	168 ^[5]			
Units: Percentage of Subjects				
number (not applicable)				
Tenderness: Any	61.3			
Tenderness: Significant	15.4			
Swelling: Any	29.4			
Swelling: Mild	19			
Swelling: Moderate	14.6			
Swelling: Severe	0			
Redness: Any	31.8			
Redness: Mild	20.9			
Redness: Moderate	13.9			
Redness: Severe	0			

Notes:

[5] - Subjects reporting yes for at least 1 day or no for all days for any local reaction.

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Percentage of Subjects Reporting Pre-specified Local Reactions: Toddler Dose (12 Months of Age)

End point title	Percentage of Subjects Reporting Pre-specified Local Reactions: Toddler Dose (12 Months of Age)
-----------------	---

End point description:

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (>7.0 cm). Subjects may be represented in more than 1 category. Safety population.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Within 4 days after toddler dose (12 months of age)

End point values	13vPnC Toddler Dose			
Subject group type	Reporting group			
Number of subjects analysed	154 ^[6]			
Units: Percentage of Subjects				
number (not applicable)				
Tenderness: Any	43.7			
Tenderness: Significant	3.8			
Swelling: Any	21.3			
Swelling: Mild	8.1			
Swelling: Moderate	15.8			
Swelling: Severe	0			
Redness: Any	22			
Redness: Mild	8.8			
Redness: Moderate	15.7			
Redness: Severe	0			

Notes:

[6] - Subjects reporting yes for at least 1 day or no for all days for any local reaction.

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Percentage of Subjects Reporting Pre-Specified Systemic Events: Infant Series Dose 1 (2 Months of Age)

End point title	Percentage of Subjects Reporting Pre-Specified Systemic Events: Infant Series Dose 1 (2 Months of Age)
-----------------	--

End point description:

Systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Subjects may be represented in more than 1 category. Safety population.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Within 4 days after dose 1 of Infant Series (2 months of age)

End point values	13vPnC Infant Series			
Subject group type	Reporting group			
Number of subjects analysed	217 ^[7]			
Units: Percentage of Subjects				
number (not applicable)				
Fever ≥ 38 degrees C but ≤ 39 degrees C	7			
Fever > 39 degrees C but ≤ 40 degrees C	0			
Fever > 40 degrees C	0			
Decreased appetite	31			
Irritability	69.8			
Increased sleep	37.2			
Decreased sleep	32.8			

Notes:

[7] - Subjects reporting yes for at least 1 day or no for all days for any systemic event.

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Percentage of Subjects Reporting Pre-Specified Systemic Events: Infant Series Dose 2 (4 Months of Age)

End point title	Percentage of Subjects Reporting Pre-Specified Systemic Events: Infant Series Dose 2 (4 Months of Age)
-----------------	--

End point description:

Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Subjects may be represented in more than 1 category. Safety population.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Within 4 days after dose 2 of Infant Series (4 months of age)

End point values	13vPnC Infant Series			
Subject group type	Reporting group			
Number of subjects analysed	198 ^[8]			
Units: Percentage of Subjects				
number (not applicable)				
Fever ≥ 38 degrees C but ≤ 39 degrees C	18.5			
Fever > 39 degrees C but ≤ 40 degrees C	0.6			
Fever > 40 degrees C	0			
Decreased appetite	29.3			
Irritability	62.2			
Increased sleep	24.5			
Decreased sleep	35.1			

Notes:

[8] - Subjects reporting yes for at least 1 day or no for all days for any systemic event.

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Percentage of Subjects Reporting Pre-Specified Systemic Events: Infant Series Dose 3 (6 Months of Age)

End point title	Percentage of Subjects Reporting Pre-Specified Systemic Events: Infant Series Dose 3 (6 Months of Age)
-----------------	--

End point description:

Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Subjects may be represented in more than 1 category. Safety population.

End point type	Other pre-specified
End point timeframe:	
Within 4 days after dose 3 of Infant Series (6 months of age)	

End point values	13vPnC Infant Series			
Subject group type	Reporting group			
Number of subjects analysed	172 ^[9]			
Units: Percentage of Subjects				
number (not applicable)				
Fever ≥38 degrees C but ≤39 degrees C	18.3			
Fever >39 degrees C but ≤40 degrees C	2.2			
Fever >40 degrees C	0			
Decreased appetite	25.7			
Irritability	63.2			
Increased sleep	22.9			
Decreased sleep	37.3			

Notes:

[9] - Subjects reporting yes for at least 1 day or no for all days for any systemic event.

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Percentage of Subjects Reporting Pre-Specified Systemic Events: Toddler Dose (12 Months of Age)

End point title	Percentage of Subjects Reporting Pre-Specified Systemic Events: Toddler Dose (12 Months of Age)
End point description:	
Systemic events (any fever ≥38 degrees C, decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Subjects may be represented in more than 1 category. Safety population.	
End point type	Other pre-specified
End point timeframe:	
Within 4 days after toddler dose (12 months of age)	

End point values	13vPnC Toddler Dose			
Subject group type	Reporting group			
Number of subjects analysed	162 ^[10]			
Units: Percentage of Subjects				
number (not applicable)				
Fever ≥38 degrees C but ≤39 degrees C	23			
Fever >39 degrees C but ≤40 degrees C	0			
Fever >40 degrees C	0			
Decreased appetite	33.8			
Irritability	46.7			

Increased sleep	17.9			
Decreased sleep	22			

Notes:

[10] - Subjects reporting yes for at least 1 day or no for all days for any systemic event.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

SAEs: Baseline through visit 7 (1 Month after last study vaccination); AEs: from signing of ICF to visit 5(1 month after Dose 3) and then from visit 6 (Toddler Dose) to visit 7. Local reactions, systemic events assessed within 4 days after each dose

Adverse event reporting additional description:

Same event may appear as both AE and serious AE. However, what is presented are distinct events. An event may be categorized as serious in 1 subject, and nonserious in another or 1 subject may experience both serious, nonserious event during study. Local reactions (LRs), systemic events (SEs) were assessed for Infant and toddler dose groups only.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	0.0

Reporting groups

Reporting group title	Infant Series 13vPnC
-----------------------	----------------------

Reporting group description:

13vPnC 0.5mL dose administered IM at 2, 4, and 6 months of age (infant series).

Other AEs (non-serious events): the number affected (n) for non-systematic (non-solicited) Other AEs n=79; systematic (solicited) Any Local Reaction n=154, 139, and 112 for Dose 1, 2, and 3 of infant series, respectively; systematic (solicited) Any Systemic Event n=182, 144, and 126 for Dose 1, 2, and 3 of infant series, respectively.

Reporting group title	After the Infant Series 13vPnC
-----------------------	--------------------------------

Reporting group description:

13vPnC 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series); assessment between 1 month after the infant series and the toddler dose.

Reporting group title	Toddler Dose 13vPnC
-----------------------	---------------------

Reporting group description:

13vPnC 0.5 mL dose administered IM at 12 months of age (toddler dose).

Other AEs (non-serious events): the number affected (n) for non-systematic (non-solicited) Other AEs n=50; systematic (solicited) Any Local Reaction n=73; systematic (solicited) Any Systemic Event n=96.

Serious adverse events	Infant Series 13vPnC	After the Infant Series 13vPnC	Toddler Dose 13vPnC
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 223 (1.35%)	3 / 223 (1.35%)	2 / 191 (1.05%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Vascular disorders			
Kawasaki's disease			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			

Myocarditis			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Seizure anoxic			
subjects affected / exposed	0 / 223 (0.00%)	0 / 223 (0.00%)	1 / 191 (0.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 223 (0.45%)	1 / 223 (0.45%)	0 / 191 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Breath holding			
subjects affected / exposed	0 / 223 (0.00%)	1 / 223 (0.45%)	0 / 191 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchiolitis			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			

subjects affected / exposed	0 / 223 (0.00%)	1 / 223 (0.45%)	0 / 191 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute sinusitis			
subjects affected / exposed	0 / 223 (0.00%)	0 / 223 (0.00%)	1 / 191 (0.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Infant Series 13vPnC	After the Infant Series 13vPnC	Toddler Dose 13vPnC
Total subjects affected by non-serious adverse events			
subjects affected / exposed	182 / 223 (81.61%)	3 / 223 (1.35%)	96 / 191 (50.26%)
Injury, poisoning and procedural complications			
Traumatic brain injury			
subjects affected / exposed	2 / 223 (0.90%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	2	0	0
Nervous system disorders			
Grand mal convulsion			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	1	0	0
Pregnancy, puerperium and perinatal conditions			
Cephalhaematoma			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	1	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	1	0	0
Deficiency Anaemia			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			

Pyrexia			
subjects affected / exposed	6 / 223 (2.69%)	0 / 223 (0.00%)	14 / 191 (7.33%)
occurrences (all)	6	0	14
Vaccination site pain			
subjects affected / exposed	0 / 223 (0.00%)	0 / 223 (0.00%)	3 / 191 (1.57%)
occurrences (all)	0	0	3
Vaccination site erythema			
subjects affected / exposed	0 / 223 (0.00%)	0 / 223 (0.00%)	2 / 191 (1.05%)
occurrences (all)	0	0	2
Vaccination site swelling			
subjects affected / exposed	0 / 223 (0.00%)	0 / 223 (0.00%)	2 / 191 (1.05%)
occurrences (all)	0	0	2
Irritability			
subjects affected / exposed	0 / 223 (0.00%)	0 / 223 (0.00%)	1 / 191 (0.52%)
occurrences (all)	0	0	1
Fever $\geq 38^{\circ}\text{C}$ but $\leq 39^{\circ}\text{C}$: Infant Series Dose 1 and Toddler dose	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Systemic Events 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[1]	14 / 199 (7.04%)	0 / 223 (0.00%)	32 / 139 (23.02%)
occurrences (all)	14	0	32
Fever $\geq 38^{\circ}\text{C}$ but $\leq 39^{\circ}\text{C}$: Infant Series Dose 2	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Systemic Events 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[2]	33 / 178 (18.54%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	33	0	0
Fever $\geq 38^{\circ}\text{C}$ but $\leq 39^{\circ}\text{C}$: Infant Series Dose 3	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Systemic Events 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[3]	26 / 142 (18.31%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	26	0	0
Fever $> 39^{\circ}\text{C}$ but $\leq 40^{\circ}\text{C}$: Infant Series Dose 2	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		

subjects affected / exposed ^[4] occurrences (all)	1 / 175 (0.57%) 1	0 / 223 (0.00%) 0	0 / 132 (0.00%) 0
Fever >39°C but ≤40°C: Infant Series Dose 3	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[5] occurrences (all)	3 / 138 (2.17%) 3	0 / 223 (0.00%) 0	0 / 191 (0.00%) 0
Decreased appetite: Infant Series Dose 1 and Toddler Dose	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[6] occurrences (all)	63 / 203 (31.03%) 63	0 / 223 (0.00%) 0	51 / 151 (33.77%) 51
Decreased appetite: Infant Series Dose 2	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[7] occurrences (all)	55 / 188 (29.26%) 55	0 / 223 (0.00%) 0	0 / 191 (0.00%) 0
Decreased appetite: Infant Series Dose 3	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[8] occurrences (all)	38 / 148 (25.68%) 38	0 / 223 (0.00%) 0	0 / 191 (0.00%) 0
Irritability: Infant Series Dose 1 and Toddler Dose	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic subjects affected / exposed ^[9] occurrences (all)	148 / 212 (69.81%) 148	0 / 223 (0.00%) 0	71 / 152 (46.71%) 71
Irritability: Infant Series Dose 2	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		

<p>alternative dictionary used: Systemic Events 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed^[10]</p> <p>occurrences (all)</p>	120 / 193 (62.18%)	0 / 223 (0.00%)	0 / 191 (0.00%)
Irritability: Infant Series Dose 3	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
<p>alternative dictionary used: Systemic Events 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed^[11]</p> <p>occurrences (all)</p>	103 / 163 (63.19%)	0 / 223 (0.00%)	0 / 191 (0.00%)
Increased sleep: Infant Series Dose 1 and Toddler Dose	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
<p>alternative dictionary used: Systemic Events 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed^[12]</p> <p>occurrences (all)</p>	77 / 207 (37.20%)	0 / 223 (0.00%)	25 / 140 (17.86%)
Increased sleep: Infant Series Dose 2	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
<p>alternative dictionary used: Systemic Events 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed^[13]</p> <p>occurrences (all)</p>	45 / 184 (24.46%)	0 / 223 (0.00%)	0 / 191 (0.00%)
Increased sleep: Infant Series Dose 3	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
<p>alternative dictionary used: Systemic Events 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed^[14]</p> <p>occurrences (all)</p>	35 / 153 (22.88%)	0 / 223 (0.00%)	0 / 191 (0.00%)
Decreased sleep: Infant Series Dose 1 and Toddler Dose	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
<p>alternative dictionary used: Systemic Events 0.0</p> <p>alternative assessment type: Systematic</p>			

subjects affected / exposed ^[15]	67 / 204 (32.84%)	0 / 223 (0.00%)	31 / 141 (21.99%)
occurrences (all)	67	0	31
Decreased sleep: Infant Series Dose 2	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic			
subjects affected / exposed ^[16]	66 / 188 (35.11%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	66	0	0
Decreased sleep: Infant Series Dose 3	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Systemic Events 0.0 alternative assessment type: Systematic			
subjects affected / exposed ^[17]	56 / 150 (37.33%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	56	0	0
Immune system disorders			
Allergy to arthropod bite			
subjects affected / exposed	0 / 223 (0.00%)	1 / 223 (0.45%)	0 / 191 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	13 / 223 (5.83%)	0 / 223 (0.00%)	8 / 191 (4.19%)
occurrences (all)	16	0	8
Gastrooesophageal reflux disease			
subjects affected / exposed	6 / 223 (2.69%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	6	0	0
Mouth ulceration			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	1	0	0
Mucous stools			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	0 / 223 (0.00%)	0 / 223 (0.00%)	7 / 191 (3.66%)
occurrences (all)	0	0	7
Hepatobiliary disorders			

Hepatomegaly subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 2	0 / 223 (0.00%) 0	0 / 191 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	5 / 223 (2.24%) 5	0 / 223 (0.00%) 0	1 / 191 (0.52%) 1
Rhinitis allergic subjects affected / exposed occurrences (all)	3 / 223 (1.35%) 5	0 / 223 (0.00%) 0	0 / 191 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	2 / 223 (0.90%) 2	0 / 223 (0.00%) 0	1 / 191 (0.52%) 2
Bronchospasm subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 1	0 / 223 (0.00%) 0	0 / 191 (0.00%) 0
Skin and subcutaneous tissue disorders			
Dermatitis diaper subjects affected / exposed occurrences (all)	3 / 223 (1.35%) 3	0 / 223 (0.00%) 0	0 / 191 (0.00%) 0
Rash maculo-papular subjects affected / exposed occurrences (all)	3 / 223 (1.35%) 3	0 / 223 (0.00%) 0	0 / 191 (0.00%) 0
Rash morbilliform subjects affected / exposed occurrences (all)	2 / 223 (0.90%) 2	0 / 223 (0.00%) 0	0 / 191 (0.00%) 0
Seborrhoeic dermatitis subjects affected / exposed occurrences (all)	2 / 223 (0.90%) 2	2 / 223 (0.90%) 2	0 / 191 (0.00%) 0
Dermatitis atopic subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 1	1 / 223 (0.45%) 1	0 / 191 (0.00%) 0
Eczema subjects affected / exposed occurrences (all)	1 / 223 (0.45%) 1	0 / 223 (0.00%) 0	0 / 191 (0.00%) 0
Erythema			

subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	1	0	0
Heat rash			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	1	0	0
Dermatitis			
subjects affected / exposed	0 / 223 (0.00%)	0 / 223 (0.00%)	1 / 191 (0.52%)
occurrences (all)	0	0	1
Prurigo			
subjects affected / exposed	0 / 223 (0.00%)	0 / 223 (0.00%)	1 / 191 (0.52%)
occurrences (all)	0	0	1
Urticaria			
subjects affected / exposed	0 / 223 (0.00%)	0 / 223 (0.00%)	1 / 191 (0.52%)
occurrences (all)	0	0	1
Tenderness (any): Infant Series Dose 1 and Toddler Dose	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[18]	134 / 211 (63.51%)	0 / 223 (0.00%)	66 / 151 (43.71%)
occurrences (all)	134	0	66
Tenderness (any): Infant Series Dose 2	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[19]	136 / 196 (69.39%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	136	0	0
Tenderness (any): Infant Series Dose 3	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[20]	100 / 163 (61.35%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	100	0	0
Tenderness (significant): Infant Series Dose 1 and Toddler Dose	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local			

Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[21]	25 / 202 (12.38%)	0 / 223 (0.00%)	5 / 132 (3.79%)
occurrences (all)	25	0	5
Tenderness (significant): Infant Series Dose 2	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[22]	23 / 183 (12.57%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	23	0	0
Tenderness (significant): Infant Series Dose 3	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[23]	22 / 143 (15.38%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	22	0	0
Swelling (any): Infant Series Dose 1 and Toddler Dose	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[24]	64 / 205 (31.22%)	0 / 223 (0.00%)	30 / 141 (21.28%)
occurrences (all)	64	0	30
Swelling (any): Infant Series Dose 2	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[25]	56 / 187 (29.95%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	56	0	0
Swelling (any): Infant Series Dose 3	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			

subjects affected / exposed ^[26]	45 / 153 (29.41%)	0 / 153 (0.00%)	0 / 141 (0.00%)
occurrences (all)	45	0	0
Swelling (mild): Infant Series Dose 1 and Toddler Dose	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[27]	51 / 203 (25.12%)	0 / 223 (0.00%)	11 / 136 (8.09%)
occurrences (all)	51	0	11
Swelling (mild): Infant Series Dose 2	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[28]	37 / 185 (20.00%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	37	0	0
Swelling (mild): Infant Series Dose 3	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[29]	28 / 147 (19.05%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	28	0	0
Swelling (moderate): Infant Series Dose 1 and Toddler Dose	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[30]	24 / 201 (11.94%)	0 / 223 (0.00%)	22 / 139 (15.83%)
occurrences (all)	24	0	22
Swelling (moderate): Infant Series Dose 2	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[31]	24 / 180 (13.33%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	24	0	0
Swelling (moderate): Infant Series Dose 3	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		

<p>alternative dictionary used: Local Reactions 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed^[32]</p> <p>occurrences (all)</p>	21 / 144 (14.58%)	0 / 223 (0.00%)	0 / 191 (0.00%)
<p>Redness (any): Infant Series Dose 1 and Toddler Dose</p> <p>alternative dictionary used: Local Reactions 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed^[33]</p> <p>occurrences (all)</p>	69 / 204 (33.82%)	0 / 223 (0.00%)	31 / 141 (21.99%)
<p>Redness (any): Infant Series Dose 2</p> <p>alternative dictionary used: Local Reactions 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed^[34]</p> <p>occurrences (all)</p>	54 / 187 (28.88%)	0 / 223 (0.00%)	0 / 191 (0.00%)
<p>Redness (any): Infant Series Dose 3</p> <p>alternative dictionary used: Local Reactions 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed^[35]</p> <p>occurrences (all)</p>	49 / 154 (31.82%)	0 / 223 (0.00%)	0 / 191 (0.00%)
<p>Redness (mild): Infant Series Dose 1 and Toddler Dose</p> <p>alternative dictionary used: Local Reactions 0.0</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed^[36]</p> <p>occurrences (all)</p>	57 / 204 (27.94%)	0 / 223 (0.00%)	12 / 136 (8.82%)
<p>Redness (mild): Infant Series Dose 2</p> <p>alternative dictionary used: Local Reactions 0.0</p> <p>alternative assessment type: Systematic</p>			

subjects affected / exposed ^[37]	36 / 185 (19.46%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	36	0	0
Redness (mild): Infant Series Dose 3	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[38]	31 / 148 (20.95%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	31	0	0
Redness (moderate): Infant Series Dose 1 and Toddler Dose	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[39]	21 / 199 (10.55%)	0 / 223 (0.00%)	22 / 140 (15.71%)
occurrences (all)	21	0	22
Redness (moderate): Infant Series Dose 2	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[40]	22 / 179 (12.29%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	22	0	0
Redness (moderate): Infant Series Dose 3	Additional description: Subjects affected and occurrences for LRs and SEs is same as data collected through e-diaries cannot be used to distinguish one occurrence from another within a subject/vaccination. Version not captured, here 0.0 is mentioned for dictionary version.		
alternative dictionary used: Local Reactions 0.0			
alternative assessment type: Systematic			
subjects affected / exposed ^[41]	20 / 144 (13.89%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	20	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	33 / 223 (14.80%)	0 / 223 (0.00%)	8 / 191 (4.19%)
occurrences (all)	40	0	10
Viral upper respiratory tract infection			
subjects affected / exposed	11 / 223 (4.93%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	13	0	0
Pharyngitis			

subjects affected / exposed	7 / 223 (3.14%)	0 / 223 (0.00%)	1 / 191 (0.52%)
occurrences (all)	9	0	1
Bronchiolitis			
subjects affected / exposed	6 / 223 (2.69%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	6	0	0
Viral rhinitis			
subjects affected / exposed	5 / 223 (2.24%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	5	0	0
Rhinitis			
subjects affected / exposed	4 / 223 (1.79%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	6	0	0
Viral pharyngitis			
subjects affected / exposed	4 / 223 (1.79%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	4	0	0
Influenza			
subjects affected / exposed	3 / 223 (1.35%)	0 / 223 (0.00%)	4 / 191 (2.09%)
occurrences (all)	3	0	4
Impetigo			
subjects affected / exposed	2 / 223 (0.90%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	2	0	0
Acarodermatitis			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	1	0	0
Body tinea			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	1	0	0
Bronchitis			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	2 / 191 (1.05%)
occurrences (all)	1	0	2
Conjunctivitis viral			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	1	0	0
Croup infectious			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	1	0	0
Cystitis			

subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	1	0	0
Oral candidiasis			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	1	0	0
Pyoderma			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	1 / 191 (0.52%)
occurrences (all)	1	0	1
Urinary tract infection			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	1 / 191 (0.52%)
occurrences (all)	1	0	1
Acute sinusitis			
subjects affected / exposed	0 / 223 (0.00%)	0 / 223 (0.00%)	1 / 191 (0.52%)
occurrences (all)	0	0	1
Ear infection			
subjects affected / exposed	0 / 223 (0.00%)	0 / 223 (0.00%)	1 / 191 (0.52%)
occurrences (all)	0	0	1
Gastroenteritis			
subjects affected / exposed	0 / 223 (0.00%)	0 / 223 (0.00%)	1 / 191 (0.52%)
occurrences (all)	0	0	1
Pharyngotonsillitis			
subjects affected / exposed	0 / 223 (0.00%)	0 / 223 (0.00%)	1 / 191 (0.52%)
occurrences (all)	0	0	1
Varicella			
subjects affected / exposed	0 / 223 (0.00%)	0 / 223 (0.00%)	1 / 191 (0.52%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Malnutrition			
subjects affected / exposed	1 / 223 (0.45%)	0 / 223 (0.00%)	0 / 191 (0.00%)
occurrences (all)	1	0	0
Decreased appetite			
subjects affected / exposed	0 / 223 (0.00%)	0 / 223 (0.00%)	1 / 191 (0.52%)
occurrences (all)	0	0	1

[32] - The number of subjects exposed to this adverse event is less than the total number of subjects

exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[33] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[34] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[35] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[36] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[37] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[38] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[39] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[40] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

[41] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Here number of subjects exposed signifies subjects reporting yes for at least 1 day or no for all days.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported